JournalsHub
.online
Find My Journal
SW

Shannon N. Westin

The University of Texas MD Anderson Cancer Center US

ORCID iD 0000-0002-1922-0156
683
Publications
12,579
Citations
58
H-Index
193
i10-Index
2.08
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Phase II study of cadonilimab monotherapy for recurrent small cell neuroendocrine carcinoma of the cervix

H. Clark, Kelly Rangel, Zhouxuan Li, Ying Yuan, Shannon Westin - Gynecologic Oncology, 2026
Cited by 0 Semantic Scholar

A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopy

Xiaotian Ma, Yu-Chun Hsu, Amma Asare, Kai Zhang, Deanna Glassman - Scientific Reports, 2025
Cited by 8 Semantic Scholar

CIRCULATING TUMOR DNA (CTDNA) AS A PROGNOSTIC MARKER IN PATIENTS WITH HIGH-RISK ENDOMETRIAL CANCER (HREC)

J. How, Morgan Bou Zerdan, Melissa Pham, Natalie Celestino, Xun Xu - International Journal of Gynecological Cancer, 2025
Cited by 0 Semantic Scholar

PHASE II RANDOMIZED CONTROLLED TRIAL OF EVEROLIMUS AND LETROZOLE WITH OR WITHOUT RIBOCICLIB IN ADVANCED/RECURRENT ENDOMETRIAL CANCER

J. How, Shannon Westin, Melissa Pham, Barrett Lawson, Minxing Chen - International Journal of Gynecological Cancer, 2025
Cited by 0 Semantic Scholar

IDENTIFYING RESPONDERS TO ENZALUTAMIDE IN ADVANCED ENDOMETRIAL CANCER: THE ENPAC STUDY

Anil Sood, E. Stur, Shannon Westin, B. Fellman, P. Soliman - International Journal of Gynecological Cancer, 2025
Cited by 0 Semantic Scholar

ARID1A as a clinical biomarker of immunotherapy response in gynecologic cancer

Ji Son, Heather Lin, C. Leung, E. Campbell, V. Holla - Gynecologic Oncology, 2025
Cited by 0 Semantic Scholar

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

Amma Asare, R. Previs, Daniel Spinosa, B. Fellman, Amelia L Scott - Gynecologic Oncology, 2025
Cited by 2 Semantic Scholar

Ovarian low-grade and high-grade serous carcinoma as a synchronous or metachronous phenomenon: A cohort of 30 cases

Allison Brodsky, Charlotte Sun, Lauren P Cobb, Shannon Westin, Anais Malpica - Gynecologic Oncology, 2025
Cited by 0 Semantic Scholar

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation

Kathleen N Moore, Shannon Westin, H. S. Chon, J. T. Pepin, E. Salinas - Gynecologic Oncology, 2025
Cited by 3 Semantic Scholar

Clinical efficacy of pembrolizumab and lenvatinib monotherapy and combination therapy in patients with platinum-resistant high-grade serous ovarian cancer

H. Clark, Kathryn Lito, B. Fellman, Samantha M Fix, A. Knisely - Gynecologic Oncology, 2025
Cited by 0 Semantic Scholar

Research Topics

Ovarian cancer diagnosis and treatment (325) Endometrial and Cervical Cancer Treatments (177) PARP inhibition in cancer therapy (135) Cancer Genomics and Diagnostics (47) BRCA gene mutations in cancer (36)

Affiliations

Twitter (United States)
US 2024 - 2024
University of North Carolina at Chapel Hill
US 2007 - 2007
Gynecologic Oncology Group
US 2022 - 2012
Novartis (Switzerland)
CH 2020 - 2020
Fox Chase Cancer Center
US 2018 - 2018

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now